MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ijms18040837

Медицинская библиотека · International journal of molecular sciences · 2017

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Almeida Antonio M, Prebet Thomas, Itzykson Raphael, Ramos Fernando, Al-Ali Haifa, Shammo Jamile, Pinto Ricardo, Maurillo Luca, Wetzel Jaime, Musto Pellegrino, Van De Loosdrecht Arjan A, Costa Maria Joao, Esteves Susana, Burgstaller Sonja, Stauder Reinhard, Autzinger Eva M, Lang Alois, Krippl Peter, Geissler Dietmar, Falantes Jose Francisco, Pedro Carmen, Bargay Joan, Deben Guillermo, Garrido Ana, Bonanad Santiago, Diez-Campelo Maria, Thepot Sylvain, Ades Lionel, Sperr Wolfgang R, Valent Peter, Fenaux Pierre, Sekeres Mikkael A, Greil Richard, Pleyer Lisa

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

Для цитирования: Almeida Antonio M, Prebet Thomas, Itzykson Raphael, Ramos Fernando, Al-Ali Haifa, Shammo Jamile, Pinto Ricardo, Maurillo Luca, Wetzel Jaime, Musto Pellegrino, Van De Loosdrecht Arjan A, Costa Maria Joao, Esteves Susana, Burgstaller Sonja, Stauder Reinhard, Autzinger Eva M, Lang Alois, Krippl Peter, Geissler Dietmar, Falantes Jose Francisco, Pedro Carmen, Bargay Joan, Deben Guillermo, Garrido Ana, Bonanad Santiago, Diez-Campelo Maria, Thepot Sylvain, Ades Lionel, Sperr Wolfgang R, Valent Peter, Fenaux Pierre, Sekeres Mikkael A, Greil Richard, Pleyer Lisa. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.. International journal of molecular sciences. 2017. DOI: 10.3390/ijms18040837.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.